
XenTech is a Patient-Derived Tumor Xenograft platform
Offering preclinical cancer models and services for translational drug development
To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.


Latest news
XenTech will attend the PARP & DDR Inhibitors Summit next week, e-Meet you there !

Company

Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....

Partnerships

Research collaborations
XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...
